On November 4, 2014, an end of phase II meeting was held successfully with FDA, at which KangLaiTe USA phase II study results, CMC and non-clinical study issues and phase III study designs were discussed with FDA.
ASCO Annual Meeting 2013: KangLaiTe-USA Interim Phase II Pancreatic Cancer Trial Data Accepted for Online Publication
On May 31, 2013, interim data from the company’s Phase II pancreatic cancer study were published in conjunction with the American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, Illinois. For more information, see http://abstracts2.asco.org/AbstView_132_115489.html.
KangLaiTe-USA Presents Interim Data on its Clinical Candidate, Kanglaite Injection, to Multinational Association of Supportive Care in Cancer Annual Conference
On June 28, 2012, KangLaiTe-USA presented interim data on its clinical candidate, Kanglaite Injection (KLTi), at the Multinational Association of Supportive Care in Cancer Annual Conference in Boston, Massachusetts. The Phase II clinical trial results included 41 patients with advanced pancreatic cancer who were given gemcitabine with or without Kanglaite Injection (KLTi) to assess the investigational product’s effect on outcome. For more information, please refer to the Publications page.